Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)
| Image |  |
|---|---|
| Description | scientific article published on 10 August 2018 |
| Author/s |
author: Joshua Zeidner Mark R Litzow |
| Publication date | August 10, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |